Theranostic Vectors to Treat Cancer with Radiometals

用放射性金属治疗癌症的治疗诊断载体

• 批准号: 493725-2016
• 负责人: Orvig, Chris
• 金额: $ 18.66万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Collaborative Health Research Projects
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=621875
• 关键词: Theranostic; Vectors; Treat; Cancer; Radiometals

The burden of cancer can be reduced by early detection and early treatment management of patients; in this regard nuclearimaging and therapy have made great contributions to clinical medicine particularly for diagnosis and have potential for muchgreater importance in therapy should the radioactivity be properly harnessed. Nuclear medicine requires injecting very smallamounts of radioactivity attached to designer molecules that are transported specifically to the area physicians need toimage or treat, resulting in low radiation doses for imaging, and minimal harm to surrounding healthy tissue for therapy.Depending on the radioactive decay emissions of a specific isotope, it can be used for diagnostic imaging, or delivery ofradiation specifically to the tumour to destroy cancer cells. Unfortunately, the current technology needed to safely andproperly incorporate these radioactive elements into a pharmaceutical in limited. The project objective is to develop noveltechnologies to harness radioactive metals for therapy and imaging of a variety of cancers. Our multidisciplinary team ofexperts from UBC, TRIUMF and the BC Cancer Agency, along with our industrial partner Nordion, will optimize theproduction of these radioisotopes, and enable technologies to securely attach the radioactive metal to a variety of"biomolecules" (molecules that are targeted specifically to specific proteins in cancer progression). By varying theradiometal, these radiopharmaceuticals can be used for both imaging and subsequent non-invasive targeted treatment ofcancers. The developments made through this project will positively affect Canadians suffering with cancer. Personal healthimplications are significant with radioactivity as dose can be personalized easily by adjusting both the affinity of the bindinginteraction to the tumour and the radiation load of the final construct.

癌症的负担可以通过对患者的早期检测和早期治疗管理来减少;在这方面，核成像和治疗对临床医学做出了巨大贡献，特别是在诊断方面，如果放射性得到适当利用，在治疗中具有更大的重要性。核医学需要注入非常少量的放射性物质，这些放射性物质附着在设计分子上，专门输送到医生需要成像或治疗的区域，从而使成像的辐射剂量很低，对周围健康组织的伤害最小。根据特定同位素的放射性衰变发射，它可以用于诊断成像，或将辐射特异性地传递到肿瘤以破坏癌细胞。不幸的是，目前的技术需要安全和适当地将这些放射性元素纳入药物有限。该项目的目标是开发新技术，利用放射性金属对各种癌症进行治疗和成像。我们来自UBC、TRIUMF和BC癌症机构的多学科专家团队，沿着我们的工业合作伙伴Nordion，将优化这些放射性同位素的生产，并使技术能够将放射性金属安全地附着到各种“生物分子”（在癌症进展中专门针对特定蛋白质的分子）上。通过改变放射性金属，这些放射性药物可用于成像和随后的癌症非侵入性靶向治疗。通过该项目取得的进展将对加拿大癌症患者产生积极影响。个人健康的影响是显着的放射性剂量可以很容易地通过调整亲和力的bindinginteraction的肿瘤和最终构建的辐射负荷。